Barclays PLC Tarsus Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 127,579 shares of TARS stock, worth $9.08 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,579
              Previous 127,579
              
        
           -0.0%
        
      
          
        Holding current value
$9.08 Million
            Previous $5.17 Million
            
        
           -0.0%
        
      
          
        % of portfolio
0.0%
            Previous 0.0%
          
        Shares
	  14 transactions
	
  Others Institutions Holding TARS
# of Institutions
215Shares Held
46.9MCall Options Held
7.8KPut Options Held
0- 
    
      Black Rock Inc. New York, NY3.27MShares$232 Million0.0% of portfolio
- 
    
      Rtw Investments, LP New York, NY3.11MShares$221 Million1.94% of portfolio
- 
    
      Paradigm Biocapital Advisors LP New York, NY2.98MShares$212 Million5.63% of portfolio
- 
    
      Jennison Associates LLC2.6MShares$185 Million0.09% of portfolio
- 
    
      Tang Capital Management LLC San Diego, CA2.45MShares$175 Million5.96% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.9B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...